Valuation: Vertex Pharmaceuticals Incorporated

Capitalization 115B 100B 94.32B 85.78B 158B 10,001B 178B 1,113B 430B 4,556B 432B 423B 16,782B P/E ratio 2025 *
29.8x
P/E ratio 2026 * 25.5x
Enterprise value 106B 92.46B 86.86B 78.99B 146B 9,210B 164B 1,025B 396B 4,196B 398B 389B 15,454B EV / Sales 2025 *
8.91x
EV / Sales 2026 * 7.54x
Free-Float
99.04%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+1.45%
1 week-2.53%
Current month+1.44%
1 month+1.76%
3 months-12.51%
6 months+13.05%
Current year+11.35%
More quotes
1 week 440
Extreme 440
457.23
1 month 427.43
Extreme 427.43
460.33
Current year 397.24
Extreme 397.245
519.68
1 year 377.85
Extreme 377.85
519.88
3 years 265.98
Extreme 265.98
519.88
5 years 176.36
Extreme 176.36
519.88
10 years 71.46
Extreme 71.46
519.88
More quotes
Manager TitleAgeSince
Chief Executive Officer 52 2020-03-31
Director of Finance/CFO 57 2019-04-09
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 65 1997-12-31
Chairman 69 2012-04-30
Director/Board Member 56 2015-06-17
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+1.45%-2.53%-4.04%+70.44% 115B
-0.78%-2.92%-11.94%+169.86% 705B
-1.08%-2.92%+3.49%-11.05% 363B
+1.22%-5.48%-50.22%+30.75% 331B
+0.01%-3.14%+8.25%+34.14% 328B
+0.35%-3.67%+4.88%-14.29% 254B
+0.25%-1.85%+2.21%+20.55% 228B
+0.04%-3.25%-15.01%+6.33% 220B
+1.29%-1.28%-38.05%-6.30% 199B
-0.19%-2.58%-5.35%+23.39% 156B
Average +0.26%-3.16%-10.58%+32.38% 289.86B
Weighted average by Cap. +0.01%-3.07%-10.87%+51.75%
See all sector performances

Financials

2025 *2026 *
Net sales 11.91B 10.38B 9.75B 8.87B 16.36B 1,034B 18.45B 115B 44.43B 471B 44.68B 43.73B 1,735B 13.22B 11.53B 10.83B 9.85B 18.17B 1,149B 20.49B 128B 49.34B 523B 49.63B 48.57B 1,927B
Net income 3.89B 3.4B 3.19B 2.9B 5.35B 338B 6.03B 37.63B 14.53B 154B 14.61B 14.3B 568B 4.57B 3.99B 3.75B 3.41B 6.28B 397B 7.09B 44.21B 17.07B 181B 17.17B 16.8B 667B
Net Debt -9.12B -7.95B -7.47B -6.79B -12.52B -792B -14.12B -88.1B -34.01B -361B -34.21B -33.48B -1,329B -15.49B -13.51B -12.69B -11.54B -21.28B -1,345B -24B -150B -57.79B -613B -58.13B -56.88B -2,257B
More financial data * Estimated data
Logo Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (60.7%), Europe (31.3%) and other (8%).
Employees
6,100
More about the company
Date Price Change Volume
25-06-18 448.40 $ +1.45% 1,380,456
25-06-17 441.99 $ -1.98% 1,363,520
25-06-16 450.91 $ -1.00% 1,030,124
25-06-13 455.45 $ -1.00% 1,021,563
25-06-12 460.06 $ +1.68% 1,074,625

Delayed Quote Nasdaq, June 18, 2025 at 04:00 pm EDT

More quotes
Trading Rating
Investor Rating
ESG MSCI
AA
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
33
Last Close Price
448.40USD
Average target price
499.87USD
Spread / Average Target
+11.48%
Consensus

Quarterly revenue - Rate of surprise